

NCT ID	NCT03488953
Title	Living Donor Liver Transplantation With Two Stage Hepatectomy for Patients With Isolated, Irresectable Colorectal Liver Metastases
Phase	Not Applicable
Date Added	2018-04-05
Location	Germany
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03476681
Title	Study of NEO-201 in Solid Tumors Expansion Cohorts
Phase	Phase 1, Phase 2
Date Added	2018-03-26
Location	Maryland, United States Virginia, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Recruiting
Drugs	NEO-201 in combination with pembrolizumab
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03475004
Title	Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer
Phase	Phase 2
Date Added	2018-03-23
Location	Colorado, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Pembrolizumab, Bevacizumab, and Binimetinib
Tags	MSS/ MMRp
NCT ID	NCT03412877
Title	Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Phase	Phase 2
Date Added	2018-01-29
Location	Maryland, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Recruiting
Drugs	Aldesleukin, Cyclophosphamide, Fludarabine, Individual Patient TCR-Transduced PBL, Pembrolizumab (Keytruda)
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03400332
Title	A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
Phase	Phase 2
Date Added	2018-01-17

Location	Arkansas, United States California, United States Colorado, United States Georgia, United States Maryland, United States Massachusetts, United States Michigan, United States Nebraska, United States Nevada, United States New Jersey, United States New York, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Texas, United States Utah, United States Virginia, United States Australia Belgium Canada France Germany Italy Poland Spain Sweden Switzerland United Kingdom
Prior IO Allowed	No
CRC-directed	No
Status	Active, not recruiting
Drugs	BMS-986253, Ipilimumab, Nivolumab
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03388632
Title	Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers
Phase	Phase 1
Date Added	2018-01-03
Location	Maryland, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Recruiting
Drugs	Ipilimumab, Nivolumab, rhIL-15, Opdivo, Yervoy
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03388190
Title	METIMMOX: Colorectal Cancer METastasis – Shaping Anti-tumor IMMunity by OXaliplatin
Phase	Phase 2
Date Added	2018-01-02
Location	Norway
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	FLOX, Nivolumab, Opdivo
Tags	MSS/ MMRp

NCT ID	NCT03368963
Title	TAS102 in Combination With NAL-IRI in Advanced GI Cancers
Phase	Phase 1, Phase 2
Date Added	2017-12-11
Location	Georgia, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Nanoliposomal Irinotecan, Trifluridine and Tipiracil Hydrochloride
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03366155
Title	Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver
Phase	Phase 2
Date Added	2017-12-08
Location	Maryland, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	5FU, cetuximab, FUDR-Dex, Irinotecan, Medtronic SynchroMed II Pump with Codman 3000 Constant Flow Pump Catheter, OneRNA, oxaliplatin, panitumumab
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03365882
Title	S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Phase	Phase 2
Date Added	2017-12-07

Location	Alaska, United States Arizona, United States Arkansas, United States California, United States Colorado, United States Connecticut, United States Florida, United States Georgia, United States Hawaii, United States Idaho, United States Illinois, United States Indiana, United States Iowa, United States Kansas, United States Kentucky, United States Louisiana, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Mississippi, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States North Carolina, United States North Dakota, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Rhode Island, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Vermont, United States Washington, United States West Virginia, United States Wisconsin, United States Wyoming, United States Puerto Rico
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	cetuximab, HER-2 testing, Irinotecan Hydrochloride, Pertuzumab, Trastuzumab, Camptosar, Erbitux, Herceptin, Perjeta
Tags	MSS/ MMRp